Enriqueta Felip
恩里克塔·费利普
MD, PhD
Head of Thoracic Cancers Unit, Medical Oncology胸部肿瘤科主任，肿瘤内科
👥Biography 个人简介
Dr. Enriqueta Felip is a globally recognized thoracic oncologist at Vall d'Hebron and a principal investigator of CheckMate-816, which established neoadjuvant nivolumab plus chemotherapy as standard care for resectable NSCLC. She leads European initiatives in perioperative immunotherapy and NSCLC biomarker research.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CheckMate-816 & Neoadjuvant Immunotherapy
Lead investigator of CheckMate-816, demonstrating that neoadjuvant nivolumab plus chemotherapy significantly improves pCR and EFS in resectable NSCLC, establishing a new perioperative immunotherapy standard.
Representative Works 代表性著作
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate-816)
New England Journal of Medicine (2022)
Phase III trial showing nivolumab + chemotherapy more than doubled pCR vs chemotherapy alone in resectable stage IB–IIIA NSCLC, now a global standard of care.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 恩里克塔·费利普 的研究动态
Follow Enriqueta Felip's research updates
留下邮箱，当我们发布与 Enriqueta Felip（Vall d'Hebron University Hospital, Barcelona）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment